This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The present study assessed the therapeutic effect of exenatide and metformin as the initial therapy on overweight/obese patients with newly diagnosed type 2 diabetes (T2D). The prospective, nonrandomized, interventional study enrolled a total of 230 overweight or obese patients with newly diagnosed T2D who were administrated exenatide or metformin hydrochloride for 12 weeks. 224/230 patients, including 106 in the exenatide group and 118 in the metformin group, completed the 12-week treatment. Both exenatide and metformin significantly decreased the Hb A1c levels in overweight/obese patients with newly diagnosed T2D (all ) were independent influencing factors for the decrease in Hb A1c level. For an initial therapy in overweight/obese patients with newly diagnosed T2D, exenatide causes a better glycemic control than metformin. Type 2 diabetes (T2D) is a common metabolic disease with high morbidity and mortality due to T2D-related complications . Obesity is a major risk factor for T2D as it induces chronic inflammation, endoplasmic reticulum stress, mitochondrial dysfunction, and insulin resistance . The impact on body weight is also considered a critical aspect of the clinical evaluation of hypoglycemic drugs. Several studies have confirmed that some hypoglycemic drugs like sulfonylureas, thiazolidinediones, or insulin tend to cause gain weight, while metformin leads to no change or mild decline in body weight . Thus, metformin is frequently used as a first-choice therapy in overweight/obese T2D patients . Glucagon-like peptide-1 (GLP-1) receptor agonist is a novel agent approved for treating T2D and has been demonstrated to induce significant weight loss in overweight/obese T2D patients [3–6]. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (Peer J) and either DOI or URL of the article must be cited. Cardiovascular disease is a major cause of mortality and morbidity in people with type 2 diabetes mellitus (T2DM). Studies have consistently identified dyslipidemia as an important risk factor for the development of macrovascular disease. The landmark United Kingdom Prospective Diabetes Study has shown that metformin therapy reduces cardiovascular events in overweight people with T2DM. This study investigates the effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed T2DM, and whether the effect, if any, is dosage-related. This cohort study enrolled individuals exceeding 20 years of age, with recent onset T2DM, who received at least 12 months of metformin monotherapy and blood tests for serum lipid at 6-month intervals. Buy proscar paypal Best site to buy accutane online Is it legal to buy viagra online uk Zoloft early side effects A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Sep 7, 2017. Comparison of Exenatide and Metformin Monotherapy in. Both exenatide and metformin significantly decreased the HbA1c levels in. Comment. Although residual confounding is possible, this study shows that initiation of metformin monotherapy versus sulfonylurea monotherapy among patients with type 2 diabetes and mild-to-moderate kidney function impairment is associated with lower risk for death. To evaluate the safety and effectiveness of metformin monotherapy for 52 weeks, including 24 weeks of treatment and a 28-week extension period for evaluation of long-term safety, in 37 Japanese pediatric patients with type 2 diabetes mellitus. This study design was an open-label, non-randomized, multicenter trial. The primary effectiveness endpoint was the changes from baseline to the final visit at 24 weeks in Hb A1c. The secondary endpoints were the rate for achieving the treatment goal, and the changes in glycated albumin, fasting blood glucose, fasting insulin, HOMA-IR, and fasting serum lipids. Metformin was administrated at the dose of 500 mg/day up to a maximum of 2000 mg/day taken in two or three divided doses. The mean change of Hb A1c at the final visit at 24 weeks for 20 metformin-naïve patients (Group A) was − 0.66 ± 0.95% and that of 17 already-on metformin patients (Group B) was − 0.98 ± 1.62%. These figures proved the effectiveness of metformin as defined before the study. Type 2 Diabetes Mellitus (T2DM) is a chronic disorder and its treatment with only metformin often does not provide optimum glycemic control. Addition of sodium glucose cotransporter 2 inhibitor (SGLT2) will improve the glycemic control in patients on metformin alone. In this study, an attempt is made to investigate the combined therapy of SGLT-2 with metformin in managing T2DM in terms of lowering Hb A1c and body weight and monotherapy using metformin alone in Hb A1c and body weight reduction. A systematic review of the randomized controlled trials has been carried out and Cochrane risk of bias tool was used for the quality assessment. Patient, Intervention, Comparison and Outcomes (PICO) technique is used to select the relevant articles to meet the objective. The studies used in this article are multicenter, double-blinded randomized controlled trials on SGLT2 inhibitors with methformin, there were a total of 3897 participants, with a range of 182 to 1186 individual study size were included. Studies showed that combined therapy were more effective in Hb A1c and body weight reduction as compared to monotherapy. Metformin monotherapy Effectiveness of vildagliptin as add‐on to metformin monotherapy., Comparison of Exenatide and Metformin Monotherapy in Overweight. Prednisone 10mgBuy erythromycin solutionOrder viagra online dubaiBuy cheap viagra ukAmoxicillin photos Cohort with suboptimal HbA1c after treatment with metformin monotherapy. an HbA1c 7% for the first time following at least 90 days on metformin therapy. Adherence to treatment guidelines in Type 2. - Semantic Scholar. Monotherapy with Metformin vs. Sulfonylureas for Type 2.. Effects of Sulfonylureas and Metformin on Cardiovascular.. Patients assigned to metformin monotherapy showed a significant benefit for glycaemia control, weight, dyslipidaemia, and diastolic blood pressure. Metformin presents a strong benefit for HbA1c when compared with placebo and diet; and a moderated benefit for glycaemia control, LDL cholesterol, and BMI or weight when compared with sulphonylureas. Randomized clinical trials of metformin in monotherapy, with results on mortality, morbility, and biochemistry. Extraction of data. RevMan 4 computer program. Apr 12, 2018. Discussion Metformin monotherapy appreciably improves dyslipidemia in statin-naive people with T2DM. Its lipid-modifying effect may be.